Seiji Mabuchi

Summary

Affiliation: Osaka University
Country: Japan

Publications

  1. ncbi Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Mol Cancer Ther 9:2411-22. 2010
  2. ncbi Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, Japan
    Int J Gynecol Cancer 22:1545-51. 2012
  3. ncbi Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Int J Gynecol Cancer 22:1389-97. 2012
  4. ncbi Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, 565 0871, Japan
    Gynecol Oncol 127:114-20. 2012
  5. ncbi G-CSF induces focal intense bone marrow FDG uptake mimicking multiple bone metastases from uterine cervical cancer: a case report and review of the literature
    S Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Eur J Gynaecol Oncol 33:316-7. 2012
  6. ncbi mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Clin Cancer Res 15:5404-13. 2009
  7. ncbi Use of monoclonal antibodies in the treatment of ovarian cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Curr Opin Obstet Gynecol 22:3-8. 2010
  8. ncbi Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Gynecol Oncol 115:482-7. 2009
  9. ncbi Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Int J Gynecol Cancer 20:834-40. 2010
  10. ncbi Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Gynecol Oncol 123:241-7. 2011

Collaborators

Detail Information

Publications42

  1. ncbi Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Mol Cancer Ther 9:2411-22. 2010
    ..Bevacizumab may be efficacious not only as a first-line treatment but also as a second-line treatment of recurrent disease in patients previously treated with cisplatin...
  2. ncbi Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, Japan
    Int J Gynecol Cancer 22:1545-51. 2012
    ..The aim of this study was to investigate the prognostic significance of elevated white blood cell (WBC) count at the time of the diagnosis of cervical cancer recurrence...
  3. ncbi Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Int J Gynecol Cancer 22:1389-97. 2012
    ..To evaluate the significance of adenosquamous carcinoma (ASC) compared with adenocarcinoma (AC) in the survival of surgically treated early-stage cervical cancer...
  4. ncbi Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, 565 0871, Japan
    Gynecol Oncol 127:114-20. 2012
    ..To evaluate the significance of adenocarcinoma (AC) compared with squamous cell carcinoma (SCC) with regard to the survival of surgically-treated early stage cervical cancer patients...
  5. ncbi G-CSF induces focal intense bone marrow FDG uptake mimicking multiple bone metastases from uterine cervical cancer: a case report and review of the literature
    S Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Eur J Gynaecol Oncol 33:316-7. 2012
    ....
  6. ncbi mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Clin Cancer Res 15:5404-13. 2009
    ..This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype...
  7. ncbi Use of monoclonal antibodies in the treatment of ovarian cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Curr Opin Obstet Gynecol 22:3-8. 2010
    ..One of the promising approaches that may improve patient outcome is the use of monoclonal antibodies (mAbs)...
  8. ncbi Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Gynecol Oncol 115:482-7. 2009
    ..The aim of this study was to evaluate the efficacy of postoperative nedaplatin-based concurrent chemoradiotherapy (CCRT) in patients with FIGO stage IA2-IIB cervical cancer with adverse risk factors...
  9. ncbi Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Int J Gynecol Cancer 20:834-40. 2010
    ..The aim of this study was to identify the prognostic factors and to establish a model for the prediction of life expectancy in patients with recurrent cervical cancer that had previously been treated with radiotherapy...
  10. ncbi Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Gynecol Oncol 123:241-7. 2011
    ..The aim of this study was to compare the treatment outcomes and adverse effects of radical hysterectomy followed by adjuvant radiotherapy with definitive radiotherapy alone in patients with FIGO stage IIB cervical cancer...
  11. ncbi The first 2 cases of granulocyte colony-stimulating factor producing adenocarcinoma of the uterine cervix
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, Japan
    Int J Gynecol Pathol 29:483-7. 2010
    ..These cases strongly indicate the aggressive nature of the G-CSF-producing cervical adenocarcinomas...
  12. ncbi Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Gynecol Oncol 120:94-100. 2011
    ....
  13. ncbi Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka 565 0871, Japan
    Gynecol Oncol 122:25-32. 2011
    ..The aim of this study was to investigate the prognostic value of pretreatment leukocytosis in patients with cervical cancer in relation to well-established conventional risk factors...
  14. ncbi The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Clin Cancer Res 17:4462-73. 2011
    ..The objective of this study was to evaluate the antitumor efficacy of trabectedin in clear cell carcinoma (CCC) of the ovary, which is regarded as an aggressive, chemoresistant, histologic subtype...
  15. ncbi Targeting mTOR signaling pathway in ovarian cancer
    S Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Curr Med Chem 18:2960-8. 2011
    ..In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitor therapy for patients with epithelial ovarian cancer...
  16. ncbi The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Gynecol Oncol 113:200-4. 2009
    ..The aim of this study was to evaluate the efficacy of paclitaxel-carboplatin (TC) for recurrent cervical cancer after definitive radiotherapy and to compare the results with non-taxane containing platinum-based chemotherapies (NTP)...
  17. ncbi Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Clin Cancer Res 14:7781-9. 2008
    ..We hypothesized that treatment with bevacizumab, a humanized recombinant anti-VEGF monoclonal antibody, could enhance antitumor response to cisplatin and prolong survival in a murine ovarian cancer model...
  18. ncbi Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone
    Seiji Mabuchi
    Departments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
    Gynecol Obstet Invest 69:224-32. 2010
    ....
  19. ncbi Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines
    Akiko Kimura
    Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
    Oncogene 23:4505-15. 2004
    ..Thus, the phosphorylation of Akt is a key event in the induction of telomerase activity by E(2) in human ovarian cancer cells...
  20. ncbi Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Medical School, Osaka, Japan
    Clin Cancer Res 10:7645-54. 2004
    ....
  21. ncbi Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin
    Seiji Mabuchi
    Departmentof Obstetrics and Gynecology, Osaka University Medical School, Suita, Osaka 565-0871, Japan
    Endocrinology 145:1302-13. 2004
    ....
  22. ncbi Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin
    Emi Arimoto-Ishida
    Department of Obstetrics and Gynecology, Osaka University Medical School, Suita, Japan
    Endocrinology 145:2014-22. 2004
    ..Our findings suggest that cisplatin causes the phosphorylation of FKHRL1 via a phosphatidylinositol 3-kinase/Akt cascade, and inhibition of this cascade sensitizes ovarian cancer cells to cisplatin...
  23. ncbi Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models
    Tsuyoshi Ohta
    Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, Japan
    Endocrinology 147:1761-9. 2006
    ..In accordance with the previously reported in vitro results, these in vivo results support the idea that combination therapy with cisplatin and a PI3K inhibitor would increase the therapeutic efficacy of cisplatin...
  24. ncbi Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan
    J Biol Chem 279:23477-85. 2004
    ..These results suggest that combination therapy of cisplatin with the NFkappaB inhibitor should increase the therapeutic efficacy of cisplatin...
  25. ncbi Estrogen and raloxifene inhibit the monocytic chemoattractant protein-1-induced migration of human monocytic cells via nongenomic estrogen receptor alpha
    Namiko Yada-Hashimoto
    Department of Obstetrics and Gynecology, School of Medicine, Osaka University, Osaka, Japan
    Menopause 13:935-41. 2006
    ..CONCLUSIONS: Our findings suggest that both E2 and raloxifene inhibited the MCP-1-induced monocyte migration through nongenomic ERalpha. This result may explain one of the antiatherosclerotic effects of E2 and raloxifene on vasculature...
  26. ncbi Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women
    Kenjiro Sawada
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    J Bone Miner Metab 27:175-81. 2009
    ..Collectively, our preliminary clinical trial showed that pQCT might be useful to monitor response to alendronate therapy, especially at the radius, and it might explain why alendronate prevents Colles' fracture...
  27. ncbi Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer
    Takeshi Hisamatsu
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Int J Gynecol Cancer 22:623-9. 2012
    ..The aim of this study was to identify predictors of the response to paclitaxel-carboplatin chemotherapy (TC) in recurrent or patients with advanced cervical cancer...
  28. ncbi The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy
    Mika Okazawa
    Department of Gynecology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    Int J Gynecol Cancer 22:490-7. 2012
    ..We investigated the prognostic significance of multiple pelvic node metastases in cervical cancer patients who were treated with radical hysterectomy plus adjuvant chemoradiotherapy...
  29. ncbi Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells
    Seiji Ogata
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Int J Gynecol Cancer 19:1473-80. 2009
    ..Our findings suggest that fasudil might be useful to prevent the progression of ovarian cancer in clinical settings...
  30. ncbi Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Medical School, Suita, Osaka 565-0871, Japan
    Endocrinology 145:49-58. 2004
    ..Thus, treatment of ovarian cancer with paclitaxel might be less effective in the setting of postoperative estrogen replacement therapy...
  31. ncbi Squamous cell carcinoma of the uterine cervix producing granulocyte colony-stimulating factor: a report of 4 cases and a review of the literature
    Yuri Matsumoto
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine 2 2 Yamadaoka, Suita, Osaka 565 0871 Japan
    Int J Gynecol Cancer 20:417-21. 2010
    ..All patients died from disease progression in less than 15 months. These cases strongly indicate the aggressive nature of the G-CSF-producing cervical cancer...
  32. ncbi Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation
    Emi Arimoto-Ishida
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka 565 0871, Japan
    Endocrinology 150:4306-15. 2009
    ..This finding should help us reach a better understanding of the pathogenesis of critical gestational diseases, such as preeclampsia...
  33. ncbi Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancer
    Fumiaki Isohashi
    Department of Radiation Oncology, Osaka University Hospital, Suita, Osaka, Japan
    Int J Radiat Oncol Biol Phys 85:728-34. 2013
    ....
  34. ncbi In vitro and in vivo assays to analyze the contribution of Rho kinase in angiogenesis
    Kenjiro Sawada
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Methods Enzymol 439:395-412. 2008
    ....
  35. ncbi Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience
    Mika Okazawa
    Department of Gynecology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka University Graduate School of Medicine, Japan
    Int J Gynecol Cancer 23:567-75. 2013
    ..To identify groups of patients who derive clinical benefit from postoperative adjuvant concurrent chemoradiotherapy (CCRT), we retrospectively investigated the survival outcomes of surgically treated early-stage cervical cancer patients...
  36. ncbi Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy
    Kenjiro Sawada
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, Japan
    Maturitas 56:343-9. 2007
    ....
  37. ncbi Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line
    Jun Kawagoe
    Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, Iidanishi, Yamagata, Japan
    J Biol Chem 278:43363-72. 2003
    ....
  38. ncbi Treatment of ovarian cancer by monoclonal antibodies
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    Discov Med 9:197-203. 2010
    ..As the preclinical results of mAb's therapeutic effects on ovarian cancer have been encouraging, further investigations are needed to establish a more effective, specific, and less toxic treatment strategy for this malignancy...
  39. ncbi Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Medical School, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    J Biol Chem 277:33490-500. 2002
    ....
  40. ncbi Cesarean scar pregnancies successfully treated with methotrexate
    Miho Muraji
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Acta Obstet Gynecol Scand 88:720-3. 2009
    ..It took 7-11 weeks for the beta-hCG level to become undetectable and 12-17 weeks for the cesarean scar pregnancy mass to disappear completely...
  41. ncbi Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan
    J Gynecol Oncol 21:93-6. 2010
    ..The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer...
  42. ncbi Nedaplatin: a radiosensitizing agent for patients with cervical cancer
    Seiji Mabuchi
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Chemother Res Pract 2011:963159. 2011
    ..Further investigations in randomized controlled trials are therefore needed...